NYSE:ATNM Actinium Pharmaceuticals (ATNM) Stock Price, News & Analysis $1.40 -0.12 (-7.89%) Closing price 10/26/2026 04:00 PM EasternExtended Trading$1.41 +0.01 (+0.79%) As of 03:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsNews and TrendsOptions ChainOwnershipSEC Filings About Actinium Pharmaceuticals Stock (NYSE:ATNM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ATNM alerts:Sign Up Key Stats Today's Range$1.36▼$1.5350-Day Range$0.97▼$1.6052-Week Range$0.74▼$1.72Volume205,764 shsAverage Volume156,732 shsMarket Capitalization$44.02 millionP/E RatioN/ADividend YieldN/APrice Target$5.00Consensus RatingBuy Company Overview Actinium Pharmaceuticals, Inc. is a biotechnology company focused on developing targeted radiotherapies for patients with hematologic malignancies, particularly those with relapsed or refractory disease. The company’s approach uses monoclonal antibodies to deliver radioactive isotopes directly to cancer cells, with the goal of selectively destroying malignant cells while limiting damage to healthy tissue. Actinium’s leading investigational product is Iomab-B, also known as iodine-131 apamistamab. It is designed as a targeted conditioning treatment to prepare patients with relapsed or refractory acute myeloid leukemia for a bone marrow transplant. The company is also developing additional antibody-based radioimmunotherapies, including programs directed at blood cancers such as acute myeloid leukemia and multiple myeloma. Actinium Pharmaceuticals is headquartered in New York City and conducts its development activities through clinical research programs in the United States and other locations. Sandesh Seth serves as the company’s chairman and chief executive officer.AI Generated. May Contain Errors. Read More Actinium Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks37th Percentile Overall ScoreATNM MarketRank™: 1.86372485399 of 5 starsActinium Pharmaceuticals scored higher than 37% of companies evaluated by MarketBeat, and ranked 699th out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingActinium Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and no sell ratings.Upside PotentialActinium Pharmaceuticals has a consensus price target of $5.00, representing about 257.1% upside from its current price of $1.40.Amount of Analyst CoverageActinium Pharmaceuticals has received no research coverage in the past 90 days.Read more about Actinium Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Actinium Pharmaceuticals are expected to grow in the coming year, from ($1.41) to ($0.77) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Actinium Pharmaceuticals is -1.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Actinium Pharmaceuticals is -1.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioActinium Pharmaceuticals has a P/B Ratio of 1.07. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for ATNM. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldActinium Pharmaceuticals does not currently pay a dividend.Dividend GrowthActinium Pharmaceuticals does not have a long track record of dividend growth. News and Social Media1.6 / 5News Sentiment-0.44 News SentimentActinium Pharmaceuticals has a news sentiment score of -0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Actinium Pharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for ATNM on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows1 people have added Actinium Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Actinium Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders0.60% of the stock of Actinium Pharmaceuticals is held by insiders.Percentage Held by Institutions27.50% of the stock of Actinium Pharmaceuticals is held by institutions.Read more about Actinium Pharmaceuticals' insider trading history. Receive ATNM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Actinium Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ATNM Stock News HeadlinesActinium Pharmaceuticals, Inc. Highlights First-In-Human Phase 1 Study of Atnm-400 A Her3-Targeted Non-Psma Radiotherapy in Prostate Cancer At Esmo 2026October 23, 2026 | marketscreener.comMActinium Advances HER3-Targeted Radiotherapy In Phase 1 Prostate Cancer StudyOctober 23, 2026 | rttnews.comTwo charts tell you the future…Gold miners are posting record cash flows, outperforming every other sector, yet mining still makes up just 1% of global equities. Garrett Goggin, CFA, CMT, has spent more than 20 years studying gold cycles and mining companies. Porter Stansberry has called him the most knowledgeable gold investor in the world.October 27 at 1:00 AM | Golden Portfolio (Ad)Actinium Pharmaceuticals to Highlight First-in-Human Phase 1 Study of ATNM-400 a HER3-Targeted Non-PSMA Radiotherapy in Prostate Cancer at ESMO 2026October 23, 2026 | prnewswire.comActinium Pharmaceuticals, Inc. Unveils Atnm-400 Data At Eanm 2026 with First-In-Human Her3-Targeted Radiotherapy Approach Beyond Psma in Prostate CancerOctober 21, 2026 | marketscreener.comMActinium Pharmaceuticals Unveils ATNM‑400 Data at EANM 2026 with a First‑In‑Human HER3‑Targeted Radiotherapy Approach Beyond PSMA in Prostate CancerOctober 20, 2026 | prnewswire.comActinium Pharmaceuticals Presents EANM 2026 Results Reinforcing ATNM-400's Pan-Tumor Potential Across Lung, Colorectal and Ovarian Cancer ModelsOctober 20, 2026 | prnewswire.comActinium Gains Ahead of ConferenceOctober 19, 2026 | baystreet.caSee More Headlines ATNM Stock Analysis - Frequently Asked Questions How have ATNM shares performed this year? Actinium Pharmaceuticals' stock was trading at $1.36 at the beginning of 2026. Since then, ATNM shares have increased by 2.9% and is now trading at $1.40. How were Actinium Pharmaceuticals' earnings last quarter? Actinium Pharmaceuticals, Inc. (NYSE:ATNM) posted its earnings results on Monday, August, 5th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.02. When did Actinium Pharmaceuticals' stock split? Actinium Pharmaceuticals's stock reverse split on the morning of Tuesday, August 11th 2020.The 1-30 reverse split was announced on Monday, August 10th 2020. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 10th 2020. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. How do I buy shares of Actinium Pharmaceuticals? Shares of ATNM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Actinium Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Actinium Pharmaceuticals investors own include NVIDIA (NVDA), Tesla (TSLA), Viking Therapeutics (VKTX), Sorrento Therapeutics (SRNE), Plug Power (PLUG), NIO (NIO) and Alibaba Group (BABA). Company Calendar Last Earnings8/05/2024Today10/26/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 ATNM's financial health is in the Green zone, according to TradeSmith. ATNM has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNYSE:ATNM Previous SymbolNYSE:ATNM CIK1388320 Webactiniumpharma.com Phone(646) 677-3870FaxN/AEmployees25Year Founded2000Price Target and Rating Average Price Target for Actinium Pharmaceuticals$5.00 High Price Target$5.00 Low Price Target$5.00 Potential Upside/Downside+257.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)$0.36 Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$48.82 million Net MarginsN/A Pretax Margin-50,512.35% Return on Equity-100.85% Return on Assets-47.89% Debt Debt-to-Equity RatioN/A Current Ratio10.25 Quick Ratio10.25 Sales & Book Value Annual Sales$35.09 million Price / Sales1.25 Cash FlowN/A Price / Cash FlowN/A Book Value$1.31 per share Price / Book1.07Miscellaneous Outstanding Shares31,441,000Free Float29,324,000Market Cap$44.02 million OptionableOptionable Beta0.26 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NYSE:ATNM) was last updated on 10/26/2026 by MarketBeat.com Staff. From Our Partners80 Days Until America's Rare Earth Supply Chain ShiftChina controls more than 90% of global rare earth alloy production, leverage it is using to restrict exports t...The Tomorrow Investor | SponsoredTwo charts tell you the future…Gold miners are posting record cash flows, outperforming every other sector, yet mining still makes up just 1%...Golden Portfolio | SponsoredWould Anthropic IPO Burst the Bubble?The biggest IPO in history is likely just weeks away… Anthropic, the company behind Claude AI, is rumoured ...Crypto 101 Media | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredHe turned $12K into $1.65M without touching Apple or TeslaTim Sykes turned $12,415 in gift money into more than $1.65 million before graduating college, without trading...Tim Sykes | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredWhy Gerardo Del Real says wait before buying uranium stocksGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredElon Musk’s Hushed FCC Filing. Dec 8th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Actinium Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Actinium Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
